Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19308305 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | August 2025 | March 2026 | Allow | 7 | 1 | 1 | Yes | No |
| 19214766 | METHOD FOR PREPARING CYANO SULFONYL FLUORIDE COMPOUNDS | May 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19177410 | 3-PHENYLPROPYLAMINE DERIVATIVE | April 2025 | December 2025 | Allow | 8 | 1 | 0 | No | No |
| 18741170 | FLUOROLACTONE AND METHOD FOR PRODUCING SAME | June 2024 | November 2025 | Allow | 17 | 2 | 0 | Yes | No |
| 18706706 | METHODS FOR PREPARING DIHYDROXYAMMONIUM 5,5'-BISTETRAZOLE-1,1'DIOLATE | May 2024 | January 2025 | Allow | 9 | 1 | 0 | No | No |
| 18631725 | Compounds | April 2024 | September 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18583627 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | February 2024 | April 2025 | Allow | 14 | 1 | 1 | No | No |
| 18442417 | NOVEL PROCESS FOR THE PREPARATION TAVABOROLE AND ITS INTERMEDIATES | February 2024 | February 2025 | Abandon | 12 | 1 | 1 | No | No |
| 18437702 | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE | February 2024 | March 2025 | Allow | 13 | 1 | 0 | No | No |
| 18425572 | Aminosteroids for the Treatment of a PTP1B Associated Disease | January 2024 | September 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18399861 | 2-PHENYL-3,4-DIHYDROPYRROLO[2,1 -F] [1,2,4]TRIAZINONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | December 2023 | March 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18395979 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | December 2023 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18536755 | Novel Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | December 2023 | July 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18532547 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | December 2023 | March 2026 | Abandon | 27 | 1 | 0 | No | No |
| 18516560 | MODULATORS OF TNF-ALPHA ACTIVITY | November 2023 | February 2025 | Allow | 15 | 2 | 1 | No | No |
| 18511627 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | November 2023 | March 2025 | Allow | 16 | 1 | 1 | No | No |
| 18511586 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | November 2023 | March 2025 | Allow | 16 | 1 | 1 | No | No |
| 18511612 | UROLITHIN DERIVATIVES AND METHODS OF USE THEREOF | November 2023 | July 2025 | Allow | 20 | 2 | 1 | No | No |
| 18388041 | METHODS FOR THE SYNTHESIS OF DEUTERATED DEXTROMETHORPHAN | November 2023 | December 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18497181 | SYNTHESIS OF CANTHARIDIN | October 2023 | September 2024 | Allow | 11 | 0 | 1 | No | No |
| 18384241 | 4-(4,5-BIS(4-BROMOPHENYL)-2-(4-METHOXYPHENYL)-1H-IMIDAZOL-1-YL)BUTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 3 | 1 | 0 | No | No |
| 18380392 | INHIBITORS OF TRYPTOPHAN DIOXYGENASES (IDO1 and TDO) AND THEIR USE IN THERAPY | October 2023 | August 2025 | Allow | 22 | 3 | 0 | No | No |
| 18379125 | N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)-2- NAPHTHIMIDAMIDE AS ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18371282 | Lipid Disulfide Prodrugs and Uses Related Thereto | September 2023 | April 2025 | Allow | 19 | 1 | 0 | No | No |
| 18463183 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | September 2023 | August 2025 | Allow | 24 | 1 | 1 | No | No |
| 18457795 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | August 2023 | September 2025 | Abandon | 25 | 0 | 1 | No | No |
| 18232198 | OXOPYRIDINE DERIVATIVES USEFUL AS AMINOCARBOXYMUCONATE SEMIALDEHYDE DECARBOXYLASE (ACMSD) INHIBITORS | August 2023 | June 2025 | Allow | 22 | 2 | 1 | Yes | No |
| 18228452 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | July 2023 | June 2025 | Abandon | 22 | 2 | 0 | No | No |
| 18223860 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | July 2023 | October 2025 | Allow | 27 | 2 | 0 | No | No |
| 18348913 | BUTYL-BRIDGED DIPHOSPHINE LIGANDS FOR ALKOXYCARBONYLATION | July 2023 | December 2024 | Abandon | 18 | 2 | 0 | No | No |
| 18216669 | (CYANO-DIMETHYL-METHYL)-ISOXAZOLES AND -[1,3,4]THIADIAZOLES | June 2023 | February 2025 | Allow | 20 | 1 | 0 | No | No |
| 18344594 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | June 2023 | November 2024 | Abandon | 17 | 0 | 1 | No | No |
| 18038029 | Method For Preparing Meta-Functionalized Pyridine Compound | May 2023 | July 2025 | Allow | 26 | 0 | 0 | No | No |
| 18313428 | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | May 2023 | November 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18248289 | PROCESS FOR THE PREPARATION OF 5-(1-CYANOCYCLOPROPYL)-PYRIDINE-2-CARBOXYLIC ACID ESTERS AMIDES AND NITRILES | April 2023 | January 2026 | Allow | 33 | 1 | 0 | No | No |
| 18296151 | CYCLOBUTYL PURINE DERIVATIVE OR SALT THEREOF | April 2023 | September 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18129857 | BISACYL DIGERMANIUM COMPOUNDS, THEIR PREPARATION AND THEIR USE AS PHOTOINITIATOR FOR RADICAL POLYMERIZATION | April 2023 | October 2024 | Abandon | 19 | 2 | 1 | No | No |
| 18175956 | CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE INHIBITORS AND AGENTS FOR BORON NEUTRON CAPTURE THERAPY | February 2023 | May 2024 | Allow | 15 | 1 | 0 | No | No |
| 18112156 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | February 2023 | July 2025 | Abandon | 29 | 2 | 0 | No | No |
| 18171950 | ANTIVIRAL COMPOUNDS | February 2023 | September 2025 | Abandon | 31 | 3 | 1 | No | No |
| 18110681 | TETHERED SILACROWN ETHERS AND ION CHANNELING APPLICATIONS THEREOF | February 2023 | November 2025 | Abandon | 33 | 4 | 1 | Yes | No |
| 18006199 | METHOD FOR LARGE-SCALE SYNTHESIS OF TETRODOTOXIN | January 2023 | March 2026 | Allow | 38 | 1 | 0 | No | No |
| 18097811 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | January 2023 | August 2025 | Allow | 31 | 4 | 1 | No | No |
| 18005704 | Liquid Bio-based Benzoxazine Resin Systems with Improved Processability and High Performance | January 2023 | February 2026 | Abandon | 37 | 0 | 1 | No | No |
| 18153947 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | January 2023 | June 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18093704 | TARGETED NITROXIDE AGENTS | January 2023 | May 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18150117 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | January 2023 | September 2025 | Allow | 33 | 1 | 1 | No | No |
| 18013069 | THIOBENZOPYRANS AND THEIR USE IN PREPARATION OF DRUGS FOR TREATMENT OF RHEUMATOID ARTHRITIS | December 2022 | July 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18146242 | TYK2 INHIBITORS AND USES THEREOF | December 2022 | September 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18145315 | OXABOROLE ESTERS AND USES THEREOF | December 2022 | December 2024 | Abandon | 24 | 0 | 1 | No | No |
| 18087302 | HETEROCYCLIC NMDA ANTAGONISTS | December 2022 | July 2023 | Allow | 7 | 1 | 0 | Yes | No |
| 18085341 | POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF | December 2022 | September 2024 | Allow | 21 | 2 | 1 | No | No |
| 18081842 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | December 2022 | April 2024 | Allow | 16 | 1 | 0 | No | No |
| 18081715 | METHOD FOR PURIFYING ETHYLENE CARBONATE THROUGH DYNAMIC CRYSTALLIZATION | December 2022 | March 2024 | Allow | 15 | 2 | 0 | No | No |
| 18079790 | CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME | December 2022 | March 2025 | Allow | 27 | 2 | 1 | No | No |
| 18070529 | HYDROXAMIC ACID-CONTAINING COMPOUND, AND PREPARATION METHOD AND USE THEREOF | November 2022 | February 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18057020 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | November 2022 | January 2025 | Allow | 26 | 2 | 0 | Yes | No |
| 17999196 | MALONITRILE DERIVATIVES | November 2022 | September 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 18056089 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND METHODS FOR USE OF THE SAME | November 2022 | February 2024 | Allow | 15 | 0 | 1 | No | No |
| 17924850 | PROCESS OF MAKING ROXADUSTAT | November 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17998569 | ENDOCYCLIC PYRIMIDINONE COMPOUNDS, AND PREPARATION METHODS, COMPOSITIONS AND USE THEREOF | November 2022 | February 2026 | Allow | 39 | 1 | 1 | No | No |
| 17983051 | PREPARATION OF SUFENTANIL CITRATE AND SUFENTANIL BASE | November 2022 | March 2025 | Allow | 29 | 3 | 0 | Yes | No |
| 17974613 | TYROSINE KINASE INHIBITORS | October 2022 | February 2025 | Abandon | 27 | 2 | 1 | No | No |
| 17971804 | HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | October 2022 | January 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 17966227 | MYC-MAX INHIBITOR COMPOUND THERAPEUTICS FOR CANCER TREATMENT, METHODS AND USES ASSOCIATED THEREWITH | October 2022 | February 2024 | Allow | 16 | 1 | 1 | No | No |
| 17996323 | Benzimidazole Derivatives | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17962781 | SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES | October 2022 | March 2024 | Allow | 17 | 1 | 0 | No | No |
| 17959826 | COMPOSITIONS AND METHODS FOR TREATING DISEASES, DISORDERS AND CONDITIONS INVOLVING TRINUCLEOTIDE REPEATS | October 2022 | November 2025 | Allow | 38 | 3 | 1 | No | No |
| 17937210 | COMPOUNDS AND METHODS FOR DETECTION OF NITRIC OXIDE | September 2022 | October 2023 | Allow | 12 | 0 | 1 | No | No |
| 17933434 | DIARYL MACROCYCLE POLYMORPH | September 2022 | August 2024 | Allow | 23 | 1 | 1 | Yes | No |
| 17907972 | METHOD FOR PREPARING NEAR-INFRARED REGION II FLUORESCENT SMALL MOLECULE | August 2022 | August 2024 | Allow | 24 | 2 | 0 | No | No |
| 17898274 | KINASE INHIBITORS | August 2022 | February 2026 | Allow | 42 | 2 | 1 | Yes | No |
| 17877498 | Aminosteroids for the Treatment of a PTP1B Associated Disease | July 2022 | March 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17869226 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | July 2022 | December 2023 | Allow | 17 | 1 | 2 | Yes | No |
| 17864133 | COMPOUNDS FOR THE MODULATION OF MYC ACTIVITY | July 2022 | March 2024 | Abandon | 20 | 0 | 1 | No | No |
| 17863941 | 4-CARBOXAMIDO-ISOINDOLINONE DERIVATIVES AS SELECTIVE PARP-1 INHIBITORS | July 2022 | May 2023 | Allow | 10 | 1 | 0 | No | No |
| 17861567 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | July 2022 | October 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17790728 | Heteroaryl compounds as inhibitors of programmed necrosis pathway, composition and method using the same | July 2022 | January 2026 | Allow | 43 | 2 | 1 | No | No |
| 17790525 | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISORDERS | July 2022 | September 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17853755 | HETEROCYCLIC GLP-1 AGONISTS | June 2022 | November 2023 | Allow | 17 | 1 | 0 | No | No |
| 17788611 | NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA | June 2022 | January 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17788275 | LIPOXYGENASE INHIBITORS | June 2022 | March 2026 | Allow | 45 | 1 | 1 | No | No |
| 17757740 | Efficient Process For Making 6-Carboxy Benzoxazole Derivatives | June 2022 | July 2025 | Allow | 36 | 1 | 0 | No | No |
| 17785760 | Highly Efficient Myeloperoxidase Activatable Imaging Agents | June 2022 | February 2026 | Allow | 44 | 2 | 1 | Yes | No |
| 17784884 | PRODUCTION OF BENZENE DERIVATIVES | June 2022 | October 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17784200 | COMPOUND AND COMPOSITION AS PDGF RECEPTOR KINASE INHIBITOR | June 2022 | August 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17832388 | ARYLAMIDES AND METHODS OF USE THEREOF | June 2022 | October 2025 | Allow | 40 | 1 | 1 | No | No |
| 17780123 | 1,8-NAPHTHYRIDIN-2-ONE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | May 2022 | July 2025 | Allow | 37 | 1 | 0 | Yes | No |
| 17664483 | METHODS FOR THE PREPARATION OF 1,3-BENZODIOXOLE HETEROCYCLIC COMPOUNDS | May 2022 | December 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17755907 | HETEROCYCLIC NMDA ANTAGONISTS | May 2022 | January 2026 | Allow | 44 | 4 | 1 | No | No |
| 17775679 | SUBSTITUTED TRICYCLIC COMPOUNDS | May 2022 | August 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17755843 | NOVEL DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | May 2022 | September 2025 | Allow | 41 | 1 | 1 | No | No |
| 17737580 | SSAO INHIBITORS AND USE THEREOF | May 2022 | January 2024 | Allow | 21 | 1 | 1 | No | No |
| 17730463 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | April 2022 | February 2024 | Allow | 22 | 2 | 0 | No | No |
| 17730438 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | April 2022 | August 2023 | Allow | 16 | 1 | 1 | No | No |
| 17726807 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | April 2022 | January 2024 | Allow | 21 | 1 | 1 | No | No |
| 17720229 | TRYPTAMINE ANALOGUES | April 2022 | February 2024 | Abandon | 22 | 3 | 1 | Yes | No |
| 17766116 | METHOD OF PRODUCING PERFLUORO(2,4-DIMETHYL-2-FLUOROFORMYL-1,3-DIOXOLANE) | April 2022 | December 2025 | Allow | 45 | 2 | 0 | Yes | No |
| 17702597 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | March 2022 | December 2023 | Abandon | 21 | 0 | 1 | No | No |
| 17655630 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | March 2022 | August 2023 | Abandon | 17 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner O DELL, DAVID K.
With a 30.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 42.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner O DELL, DAVID K works in Art Unit 1621 and has examined 325 patent applications in our dataset. With an allowance rate of 84.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 37 months.
Examiner O DELL, DAVID K's allowance rate of 84.9% places them in the 61% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by O DELL, DAVID K receive 1.93 office actions before reaching final disposition. This places the examiner in the 47% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by O DELL, DAVID K is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +12.2% benefit to allowance rate for applications examined by O DELL, DAVID K. This interview benefit is in the 48% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 27.3% of applications are subsequently allowed. This success rate is in the 47% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 55.6% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 52% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 72.2% of appeals filed. This is in the 60% percentile among all examiners. Of these withdrawals, 65.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 46% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 12.9% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.2% of allowed cases (in the 85% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.